Abstract:BACKGROUD AND PURPOSE Continuous efforts have been made to move towards maintaining the beneficial anti‐inflammatory functions of glucocorticoids (GCs) while minimizing side effects. Here, we investigated the selective glucocorticoid receptor (GR) modulator‐like properties of a plant‐derived compound caesaldekarin e (CA‐e). EXPERIMENTAL APPROACH The therapeutic efficacy of CA‐e was evaluated in several mouse models, including dextran sulfate sodium‐induced colitis, ovalbumin‐induced lung allergic inflammation, imiquimod‐induced psoriasis‐like skin inflammation and skin atrophy. The action of CA‐e targeting the GR was analysed using molecular docking, cellular thermal shift assays and microscale thermophoresis. Other methods included DNA–protein pull‐down assays and mass spectrometry. KEY RESULTS CA‐e selectively inhibited positive GC response element ((+) GRE)‐mediated direct transactivation while maintaining and even enhancing the anti‐inflammatory effects of treatment with dexamethasone (Dex). Both CA‐e alone and in combination with Dex efficiently alleviated inflammation in several mouse models with milder side effects compared with Dex alone. Mechanistically, CA‐e inhibited the formation of dimers by binding to the dimerization interface located in the ligand‐binding domain of GR, and facilitated embryonic ectoderm development (EED) that is involved in the regulation of transcriptional repression to compete for binding to (+) GRE, eventually leading to the repression of (+) GRE‐regulated genes. In addition, CA‐e repressed NF‐κB‐dependent genes by enhancing the interaction between GR and p65. CONCLUSIONS AND IMPLICATIONS Our results reveal that CA‐e is a novel GR modulator with strong potency to attenuate the side effects of GC therapy and can be used as a potential molecular tool for deciphering GR signalling.

Discovery of novel non-steroidal selective glucocorticoid receptor modulators by structure- and IGN-based virtual screening, structural optimization, and biological evaluation

Discovery of a novel nonsteroidal selective glucocorticoid receptor modulator by virtual screening and bioassays

Discovery and Optimization of N -Acyl-6-sulfonamide-tetrahydroquinoline Derivatives as Novel Non-Steroidal Selective Glucocorticoid Receptor Modulators

Discovery of Novel GR Ligands toward Druggable GR Antagonist Conformations Identified by MD Simulations and Markov State Model Analysis

Protopanaxadiol Derivative: A Plant Origin of Novel Selective Glucocorticoid Receptor Modulator with Anti-inflammatory Effect

A High-Throughput Chemical Screen Identifies Novel Inhibitors and Enhancers of Anti-Inflammatory Functions of the Glucocorticoid Receptor

Identification of 20(R, S)-protopanaxadiol and 20(R, S)-protopanaxatriol for Potential Selective Modulation of Glucocorticoid Receptor.

Channel Expansion in the Ligand-Binding Domain of the Glucocorticoid Receptor Contributes to the Activity of Highly Potent Glucocorticoid Analogues

The Glucocorticoid Receptor Agonistic Modulators CpdX and CpdX-D3 Do Not Generate the Debilitating Effects of Synthetic Glucocorticoids

A novel strategy for development of glucocorticoids through non-genomic mechanism

A ligand-specific kinetic switch regulates glucocorticoid receptor trafficking and function

A plant‐derived glucocorticoid receptor modulator with potency to attenuate the side effects of glucocorticoid therapy

Identification of a selective glucocorticoid receptor ligand for the treatment of chronic inflammation in type 2 diabetes mellitus.

Natural and Synthetic Compounds As Dissociated Agonists of Glucocorticoid Receptor

Improved Glucocorticoid Receptor Ligands: Fantastic Beasts, but How to Find Them?

New Insights into the Anti-inflammatory Mechanisms of Glucocorticoids: An Emerging Role for Glucocorticoid-Receptor-Mediated Transactivation

The novel strategy of glucocorticoid drug development via targeting nongenomic mechanisms

Discovery of novel ocotillol derivatives modulating glucocorticoid receptor/NF-κB signaling for the treatment of sepsis

Structures and mechanism for the design of highly potent glucocorticoids

Glucocorticoid Receptor Modulators CpdX and CpdX-D3 Exhibit the Same in Vivo Antiinflammatory Activities As Synthetic Glucocorticoids.

Merging Natural Product Structures with Pharmaceutical Leads: Unnatural Enantiomers of Estranes as Glucocorticoid Receptor Modulators That Suppress TNF-α and IL-6 Release